SL
ATNM icon

Sentinus LLC’s Actinium Pharmaceuticals ATNM Stock Holding History

Sentinus LLC’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.24M Buy
167,275
+18,225
+12% +$155K 0.39% 49
2023
Q1 		$1.41M Buy
149,050
+126,050
+548% +$1.33M 0.47% 44
2022
Q4 		$272K Buy
23,000
+500
+2% +$5.07K 0.16% 90
2022
Q3 		$166K Buy
+22,500
New +$140K 0.1% 104

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sentinus LLC's ATNM Position: Q2 2023 in Review

Sentinus LLC increased its Actinium Pharmaceuticals (ATNM) stake by 12% in Q2 2023, buying an estimated $155K and bringing the position to 167,275 shares worth $1.24M. The position accounts for 0.39% of the portfolio, ranked #49.

Sentinus LLC first reported a position in ATNM in Q3 2022 and has held it in 4 quarters since. The position peaked at $1.41M in Q1 2023. 71 funds tracked by Wall St. Rank hold ATNM as of Q2 2023.

  • Sentinus LLC held 167,275 shares of Actinium Pharmaceuticals worth $1.24M as of Q2 2023.
  • Sentinus LLC bought 18,225 Actinium Pharmaceuticals shares in Q2 2023, an estimated $155K.
  • Actinium Pharmaceuticals made up 0.39% of Sentinus LLC's portfolio in Q2 2023, its #49 holding.
  • Sentinus LLC first reported a position in Actinium Pharmaceuticals in Q3 2022 and has held it in 4 quarters since.
  • Sentinus LLC's Actinium Pharmaceuticals position peaked at $1.41M in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2023.

Based on Sentinus LLC's 13F filing for Q2 2023, filed 14 Aug 2023.